Engineered immune cells take on advanced liver cancer in early trial
NCT ID NCT05155189
First seen Jan 11, 2026 · Last updated Jun 01, 2026 · Updated 14 times
Summary
This early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that cannot be removed by surgery. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to check safety and see if the treatment can shrink tumors. About 72 adults whose cancer has worsened after standard therapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of Zhengzhou University
RECRUITINGZhengzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
the First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.